{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:44:58Z","timestamp":1786373098120,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK120518"],"award-info":[{"award-number":["R01DK120518"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K24DK101828"],"award-info":[{"award-number":["K24DK101828"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG055781"],"award-info":[{"award-number":["R01AG055781"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Mortality from benzodiazepine\/opioid interactions is a growing concern in light of the opioid epidemic. Patients on hemodialysis suffer from a high burden of physical\/psychiatric conditions, which are treated with benzodiazepines, and they are three times more likely to be prescribed opioids than the general population. Therefore, we studied mortality risk associated with short- and long-acting benzodiazepines and their interaction with opioids among adults initiating hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>The cohort of 69,368 adults initiating hemodialysis (January 2013 to December 2014) was assembled by linking US Renal Data System records to Medicare claims. Medicare claims were used to identify dispensed benzodiazepines and opioids. Using adjusted Cox proportional hazards models, we estimated the mortality risk associated with benzodiazepines (time varying) and tested whether the benzodiazepine-related mortality risk differed by opioid codispensing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Within 1 year of hemodialysis initiation, 10,854 (16%) patients were dispensed a short-acting benzodiazepine, and 3262 (5%) patients were dispensed a long-acting benzodiazepine. Among those who were dispensed a benzodiazepine during follow-up, codispensing of opioids and short-acting benzodiazepines occurred among 3819 (26%) patients, and codispensing of opioids and long-acting benzodiazepines occurred among 1238 (8%) patients. Patients with an opioid prescription were more likely to be subsequently dispensed a short-acting benzodiazepine (adjusted hazard ratio, 1.66; 95% confidence interval, 1.59 to 1.74) or a long-acting benzodiazepine (adjusted hazard ratio, 1.11; 95% confidence interval, 1.03 to 1.20). Patients dispensed a short-acting benzodiazepine were at a 1.45-fold (95% confidence interval, 1.35 to 1.56) higher mortality risk compared with those without a short-acting benzodiazepine; among those with opioid codispensing, this risk was 1.90-fold (95% confidence interval, 1.65 to 2.18;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>interaction<\/jats:sub>\n                      &lt;0.001). In contrast, long-acting benzodiazepine dispensing was inversely associated with mortality (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72 to 0.99) compared with no dispensing of long-acting benzodiazepine; there was no differential risk by opioid dispensing (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>interaction<\/jats:sub>\n                      =0.72).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Codispensing of opioids and short-acting benzodiazepines is common among patients on dialysis, and it is associated with higher risk of death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.13341019","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T22:39:32Z","timestamp":1590532772000},"page":"794-804","source":"Crossref","is-referenced-by-count":18,"title":["Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis"],"prefix":"10.2215","volume":"15","author":[{"given":"Abimereki D.","family":"Muzaale","sequence":"first","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Daubresse","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjae","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia M.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[{"name":"Department of Medicine, St. Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-4849","authenticated-orcid":false,"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3013-925X","authenticated-orcid":false,"given":"Mara","family":"McAdams-DeMarco","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.healthpol.2010.03.008","article-title":"Patterns in the use of benzodiazepines in British Columbia: Examining the impact of increasing research and guideline cautions against long-term use","volume":"97","author":"Cunningham","year":"2010","journal-title":"Health Policy"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am J Prev Med"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am J Public Health"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/pds.1920","article-title":"General exposures to prescription medications by race\/ethnicity in a population-based sample: Results from the Boston Area Community Health Survey","volume":"19","author":"Hall","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2215\/CJN.02590316","article-title":"Anxiety in patients treated with hemodialysis","volume":"11","author":"Cohen","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ajkd.2016.07.031","article-title":"Sleep disorders, restless legs syndrome, and uremic pruritus: Diagnosis and treatment of common symptoms in dialysis patients","volume":"69","author":"Scherer","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0272-6386(00)70037-0","article-title":"High prevalence of alcoholism in dialysis patients","volume":"35","author":"Hegde","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/sdi.12196","article-title":"Pain in chronic kidney disease: A scoping review","volume":"27","author":"Davison","year":"2014","journal-title":"Semin Dial"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","article-title":"The prevalence of symptoms in end-stage renal disease: A systematic review","volume":"14","author":"Murtagh","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.drugalcdep.2017.05.047","article-title":"Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances","volume":"178","author":"Kandel","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"j2941","DOI":"10.1136\/bmj.j2941","article-title":"Benzodiazepines and risk of all cause mortality in adults: Cohort study","volume":"358","author":"Patorno","year":"2017","journal-title":"BMJ"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: Case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/sj.ki.5001832","article-title":"Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan","volume":"70","author":"Fukuhara","year":"2006","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.ki.5002548","article-title":"Benzodiazepine use and mortality of incident dialysis patients in the United States","volume":"72","author":"Winkelmayer","year":"2007","journal-title":"Kidney Int"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000495353","article-title":"Trends in opioid prescribing among hemodialysis patients, 2007-2014","volume":"49","author":"Daubresse","year":"2019","journal-title":"Am J Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1681\/ASN.2017010098","article-title":"Opioid prescription, morbidity, and mortality in United States dialysis patients","volume":"28","author":"Kimmel","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/jgs.15740","article-title":"Psychoactive medications and adverse outcomes among older adults receiving hemodialysis","volume":"67","author":"Ishida","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 9","key":"B21-20230813","first-page":"31","article-title":"Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds","volume":"66","author":"Griffiths","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050422","article-title":"Benzodiazepine self-administration in humans and laboratory animals\u2014implications for problems of long-term use and abuse","volume":"134","author":"Griffiths","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-198706000-00012","article-title":"The alprazolam to clonazepam switch for the treatment of panic disorder","volume":"7","author":"Herman","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"ITC6-1","DOI":"10.7326\/0003-4819-159-11-201312030-01006","article-title":"In the clinic. Generalized anxiety disorder","volume":"159","author":"Patel","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl E1","key":"B25-20230813","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.9058se1c.04gry","article-title":"Major depressive disorder treatment guidelines in America and Europe","volume":"71","author":"Davidson","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2017.6996","article-title":"Treating anxiety in 2017: Optimizing care to improve outcomes","volume":"318","author":"Stein","year":"2017","journal-title":"JAMA"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13341019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:20Z","timestamp":1786369340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13341019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13341019","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]}}}